



FDA Approval Decisions Report February-April 2008

Jeremy Zhou
Senior Analyst
415-782-0454, x158
jzhou@reveredata.com

Daniel Grundig
Analyst
415-782-0454, x176
dgrundig@reveredata.com

Overview

For investors in pharmaceutical and biotech companies, rigorous monitoring of drug pipelines is essential. No milestone is more influential than the FDA approval decision date, frequently called the PDUFA date (from Prescription Drug User Fee Act).

This Revere Report features **companies with expected FDA approval decision dates in the next three months**. To provide further insights into **each drug candidate's likelihood of approval and competitive landscape**, the FDA Approval Decisions Report includes **key data based on Revere's patented classification system and proprietary pipeline database** - specifically, whether each drug candidate:

- utilizes a mechanism of action already approved by the FDA in other drugs
- faces two or fewer alternative drugs with the same mechanism of action for the same indication
- would be the first or second FDA approved drug for the company

Contents

- Recent Approval Results/Updates
- Expected PDUFA Dates in the Next Three Months
- Price and Financial Info

Copyright 2007 by Revere Data, LLC. All rights reserved.

Notes:

1. Some expected PDUFA (Prescription Drug User Fee Act) dates are Revere estimates based on NDA (New Drug Approval) submission dates. Companies are not obligated to disclose NDA submission dates or PDUFA dates, and the FDA may change its approval decision date without prior notice.
2. Drugs developed by private firms or by companies not traded publicly in the U.S. are excluded from this analysis.

Disclaimer:

Revere Data is an independent provider of investment research and information and does not offer broker / dealer, money management, hedge fund management, investment advisory, or investment banking services.

The information contained in this report is based on a limited analysis of qualitative, statistical, and financial data and should not be interpreted as recommendations based on a complete investment evaluation. The information is based on sources that Revere Data believes to be reliable, but no representation, express or implied, is made with respect to the accuracy, completeness, reliability, or timeliness. The information is subject to change without notice, and Revere Data does not accept responsibility to update it.

Revere Data does not accept responsibility or liability for any direct, indirect, special, consequential, or other losses or damages of any kind whatsoever arising out of access to, or use of, this report or any information contained in it.

For more information on Revere's independent research data and investment analytics, please contact us as follows:

Revere Data, LLC | 60 East 42nd St. Suite 716 | New York, NY 110165
866.REVERE9 (866.738.3739) | sales@reveredata.com | www.reveredata.com

Recent Approval Results/Updates

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Previous Expected PDUFA Date	Approval results/update
Axcan Pharma Inc. (USA) (AXCA) / Ultrase (Pancrelipase)/Ultrase MT (Pancrelipase)				
	Chronic Pancreatitis, Exocrine Pancreatic Insufficiency, Pancreatic Deficiency Related To Cystic Fibrosis (CF)	Enzyme Replacement Therapy	02/01/2008	Result Pending
GlaxoSmithKline plc (ADR) (GSK) / Infanrix-IPV/Kinrix (Diphtheria, Tetanus, Acellular Pertussis-Inactivated Polio Virus Vaccine (DTaP-IPV))				
	Diphtheria, Tetanus, Acellular Pertussis And Polio Vaccine	Diphtheria/Tetanus/Acellular Pertussis (DTaP)	February 2008	Result Pending
Merck & Co., Inc. (MRK) / Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine)				
	Vaginal And Vulvar Cancer Vaccine	Papillomavirus, Papillomavirus Vaccines	02/15/2008	Result Pending
sanofi-aventis (ADR) (SNY) / Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine)				
	Vaginal And Vulvar Cancer Vaccine	Papillomavirus, Papillomavirus Vaccines	02/15/2008	Result Pending
Abbott Laboratories (ABT) / KOS Pharmaceuticals Simcor (Niacin/Simvastatin)				
	Hypercholesterolemia, Dyslipidemia	Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)	02/20/2008	Result Pending

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases.

Expected PDUFA Dates in the Next Three Months

February Drug Candidates

Companies

Bristol Myers Squibb Co. (BMY)
 CV Therapeutics, Inc. (CVTX)
 Cephalon, Inc. (CEPH)
 Eisai Co., Ltd (ADR) (ESALY)
 Eli Lilly & Co. (LLY)
 Genta Incorporated (GNTA)
 Johnson & Johnson (JNJ)
 QLT Inc. (USA) (QLTI)
 Regeneron Pharmaceuticals, Inc. (REGN)
 Spectrum Pharmaceuticals, Inc. (SPPI)

Sectors

I Biopharmaceuticals

 Dermatology
 Digestive System
 Immunology
 Infectious Diseases
 Neurology
 Oncology
I Medical Devices
 Cardiology

Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Regeneron Pharmaceuticals, Inc. (REGN) / Rilonacept (Interleukin-1 Cytokine Trap)						
	CIAS1-Associated Periodic Syndrome (CAPS)	Interleukin-1 Receptor Antagonists (IL-1 Antagonists)	<u>02/29/2008</u>	Yes	Yes Only Candidate with This PMOA for This Indication	Yes
Eli Lilly & Co. (LLY) / Zyprexa Adhera (Intramuscular Olanzapine Pamoate Depot)						
	Once Every 2 To 4 Weeks Long Acting Treatment Of Schizophrenia	Monoaminergic Antagonists	March 2008	Yes	Yes Risperdal/Risperdal Consta (Risperidone) / (JNJ) Seroquel XR (Quetiapine Fumarate Sustained Release) / (AZN)	No
Eisai Co., Ltd (ADR) (ESALY) / MGj Pharma Aloxi (Palonosetron)						
	Postoperative Nausea And Vomiting	Serotonin Receptor Antagonists	<u>03/04/2008</u>	Yes	No Multiple Drugs	No
Spectrum Pharmaceuticals, Inc. (SPPI) / ISO-vorin (Levofolinic Acid)						
	Osteosarcoma (Bone Cancer)	Folic Acid Derivatives	<u>03/07/2008</u>	Yes	Yes Only Candidate with This PMOA for This Indication	Yes
CV Therapeutics, Inc. (CVTX) / Regadenoson						
	Diagnostic Cardiac Stress Test Used To Increase Blood Flow In Patients Undergoing Cardiac Perfusion Imaging Studies	Stress/Exercise Test	03/14/2008	No	Yes Binodenoson / (KG)	Yes
Bristol Myers Squibb Co. (BMY) / Abilify (Aripiprazole)/Abilify Discmelt (Aripiprazole Orally Disintegrating Tablet)						
	Bipolar I Disorder, Manic Or Mixed Episode With Or Without Psychotic Features In Pediatric Patients Aged 10-17	Serotonin/Dopamine Receptor Partial Agonists	03/14/2008	Yes	Yes Only Candidate with This PMOA for This Indication	No
Genta Incorporated (GNTA) / Genasense (Oblimersen Sodium)						
	Chronic Lymphocytic Leukemia (CLL) In Combination With Fludarabine and Cyclophosphamide	Antisense Agents	03/14/2008	Yes	Yes Only Candidate with This PMOA for This Indication	No
Johnson & Johnson (JNJ) / Ceftobiprole						

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Company (Symbol) / Drug Candidate						
	Complicated Skin And Skin Structure Infections (cSSSI), Including Those Caused By Methicillin-Resistant Staphylococcus aureus (MRSA)	Cephalosporin Derivatives	<u>03/18/2008</u>	Yes	Yes Only Candidate with This PMOA for This Indication	No
Cephalon, Inc. (CEPH) / Treanda (Bendamustine Hydrochloride)						
	Chronic Lymphocytic Leukemia (CLL)	Nitrogen Mustard Type	03/21/2008	Yes	Yes Cytosan/Lyophilized Cytosan (Cyclophosphamide) / (BMY)	No
QLT Inc. (USA) (QLTI) / ACZONE Gel (Dapsone Topical Gel)						
	Treatment Of Moderate To Severe Acne Vulgaris Without Prior Blood Monitoring And Screening Of G6PD	Sulfonamides	03/28/2008	Yes	Yes Only Candidate with This PMOA for This Indication	No











Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? 1st/2nd Drug -- 1st or 2nd FDA Approved Drug of the Company?

March Drug Candidates

Companies

AVANT Immunotherapeutics, Inc. (AVAN)
 Alcon, Inc. (ACL)
 Biovail Corporation (USA) (BVF)
 Bristol Myers Squibb Co. (BMY)
GlaxoSmithKline plc (ADR) (GSK) [2]
 Johnson & Johnson (JNJ)
Merck & Co., Inc. (MRK) [2]
 Neurochem Inc. (USA) (NRMX)
 POZEN Inc. (POZN)
Schering-Plough Corporation (SGP) [2]
 Sciele Pharma Inc. (SCRX)
 Shire plc (ADR) (SHPGY)
 Solvay S.A. (ADR) (SVYSY)
 Sucampo Pharmaceuticals, Inc. (SCMP)
 Warner Chilcott Ltd. (WCRX)

Sectors

- I** Biopharmaceuticals
 -  Allergies
 -  Dermatology
 -  Digestive System
 -  Endocrinology/Metabolism
 -  Immunology
 -  Infectious Diseases
 -  Musculoskeletal System
 -  Neurology
 -  Oncology
 -  Ophthalmology

Notes:

1. Some drug candidates are filed jointly by two companies.
2. Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Alcon, Inc. (ACL) / Tobradex ST (Tobramycin/Dexamethasone)						
	Steroid-Responsive Inflammatory Ocular Conditions Associated With Bacterial Infections	Aminoglycosides/Steroidal Anti-Inflammatory Drugs (SAID), Antibacterial Agents/Steroidal Anti-Inflammatory Drugs (SAID)	April 2008	Yes	No Multiple Drugs	No
Schering-Plough Corporation (SGP) / PEG-Intron A (Peginterferon Alfa-2b)						
	Malignant Melanoma (Skin Cancer)	Interferons	April 2008	Yes	Yes Only Candidate with This PMOA for This Indication	No
Neurochem Inc. (USA) (NRMX) / Kiacta (Eprodisate)/Formerly Fibrillex						
	Amyloid A Amyloidosis (AA Amyloidosis)	Glycosaminoglycan (GAG) Mimetic Agents	<u>04/02/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	Yes
Johnson & Johnson (JNJ) / Doribax (Doripenem)						
	Nosocomial Pneumonia	Carbapenems	04/04/2008	Yes	Yes Invanz (Ertapenem Sodium) / (MRK)	No
Bristol Myers Squibb Co. (BMY) / Orencia (Abatacept)						
	Juvenile Rheumatoid Arthritis (JRA) Who Have Had An Inadequate Response To One Or More DMARDs	Immunosuppressants	04/07/2008	Yes	Yes Only Candidate with This PMOA for This Indication	No
Solvay S.A. (ADR) (SVYSY) / Unimed Pharmaceuticals Androgel (Testosterone Gel)						
	Primary Or Secondary Hypogonadism In Male Adolescents Ages 13-17 Years Old, Constitutional Delay In Growth And Puberty (CDGP) In Male Adolescents	Androgens	04/14/2008	Yes	Yes Only Candidate with This PMOA for This Indication	No
Sciele Pharma Inc. (SCRX) / Head Lice Asphyxiate						
	Head Lice Treatment	Asphyxiates	<u>04/15/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	No
POZEN Inc. (POZN) / Treximet (Naproxen/Sumatriptan)						

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
	First-Line Therapy For Acute Migraine Attacks	Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Selective Serotonin Receptor Agonists	<u>04/15/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	Yes
GlaxoSmithKline plc (ADR) (GSK) / Treximet (Naproxen/Sumatriptan)						
	First-Line Therapy For Migraine Headaches	Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Selective Serotonin Receptor Agonists	<u>04/15/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	No
Biovail Corporation (USA) (BVF) / BVF-033 (Once-Daily Bupropion Salt)						
	Depression	Serotonin/Norepinephrine Reuptake Inhibitors	<u>04/23/2008</u>	Yes	Yes Tyco Healthcare Tofranil (Imipramine Hydrochloride) / (COV) Cymbalta (Duloxetine Hydrochloride) / (LLY)	No
AVANT Immunotherapeutics, Inc. (AVAN) / Rotarix (Rotavirus Vaccine)						
	Rotavirus Gastroenteritis Vaccine	Rotavirus	<u>04/25/2008</u>	Yes	Yes Rotateq / (MRK)	Yes
GlaxoSmithKline plc (ADR) (GSK) / Rotarix (Rotavirus Vaccine)						
	Rotavirus Gastroenteritis Vaccine	Rotavirus	<u>04/25/2008</u>	Yes	Yes Rotateq / (MRK)	No
Shire plc (ADR) (SHPGY) / Vyvanse (Lisdexamfetamine Dimesylate)/Formerly NRP104						
	Attention Deficit Hyperactivity Disorder (ADHD) In Adult Patients 18-55 Years Of Age	Sympathomimetic Agents	<u>04/28/2008</u>	Yes	Yes Dexedrine (Dextroamphetamine Sulfate) / (GSK)	No
Merck & Co., Inc. (MRK) / Claritin (Loratadine)/Singulair (Montelukast)						
	Seasonal Allergic Rhinitis (SAR)	Antihistamines/Leukotriene Receptor Antagonists	<u>04/28/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	No
Schering-Plough Corporation (SGP) / Claritin (Loratadine)/Singulair (Montelukast)						
	Seasonal Allergic Rhinitis (SAR)	Antihistamines/Leukotriene Receptor Antagonists	<u>04/28/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	No
Sucampo Pharmaceuticals, Inc. (SCMP) / Amitiza (Lubiprostone)						
	Irritable Bowel Syndrome (IBS) With Constipation	Chloride Channel Activators	<u>04/29/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	Yes
Warner Chilcott Ltd. (WCRX) / Taclonex Scalp Gel (Calcipotriene/Betamethasone Dipropionate)						
	Scalp Psoriasis Vulgaris	Vitamin D Analogs/Steroidal Anti-Inflammatory Drugs (SAID)	<u>04/29/2008</u>	Yes	Yes Only Candidate with This PMOA for This Indication	No
Merck & Co., Inc. (MRK) / Cordaptive (ER Niacin/Laropiprant)/Formerly MK-0524A						
	Adjunctive Therapy To Diet For The Treatment Of Elevated LDL Cholesterol, Low HDL Cholesterol And Elevated Triglycerides Levels	Free Fatty Acid Inhibitors/Prostaglandin Inhibitors	<u>04/29/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	No

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? 1st/2nd Drug -- 1st or 2nd FDA Approved Drug of the Company?

April Drug Candidates

Companies

Abbott Laboratories (ABT)
 Akorn, Inc. (AKRX)
 Discovery Laboratories, Inc. (DSCO)
 Ligand Pharmaceuticals Inc. (LGND)
 Progenics Pharmaceuticals, Inc. (PGNX)
 Salix Pharmaceuticals, Ltd. (SLXP)
 The Medicines Company (MDCO)

Wyeth (WYE) [2]

Sectors

- I Biopharmaceuticals
 - Digestive System
 - Immunology
 - Musculoskeletal System
 - Pain Management
 - Respiratory System
 - Surgery

Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Progenics Pharmaceuticals, Inc. (PGNX) / MNTX (Subcutaneous Methylalntrexone)						
	Opioid-Induced Constipation (OIC) In Patients Receiving Palliative Care	Opioid Receptor Antagonists	<u>04/30/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	Yes
Wyeth (WYE) / MNTX (Subcutaneous Methylalntrexone)						
	Opioid-Induced Constipation (OIC) In Patients Receiving Palliative Care	Opioid Receptor Antagonists	<u>04/30/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	No
Discovery Laboratories, Inc. (DSCO) / Surfaxin (Lucinactant)						
	Prevention Of Respiratory Distress Syndrome In Premature Infants (RDS)	Surfactants	<u>05/01/2008</u>	Yes	No Multiple Drugs	Yes
Ligand Pharmaceuticals Inc. (LGND) / Viviant (Bazedoxifene)						
	Treatment Of Postmenopausal Osteoporosis	Selective Estrogen Receptor Modulators (SERM)	May 2008	Yes	No Multiple Drugs	Yes
Wyeth (WYE) / Viviant (Bazedoxifene)						
	Treatment Of Postmenopausal Osteoporosis	Selective Estrogen Receptor Modulators (SERM)	May 2008	Yes	No Multiple Drugs	No
Akorn, Inc. (AKRX) / Akten Ophthalmic Gel (Ocular Anesthetic Formulation)						
	Ocular Anesthesia	Analgesics/Opioids	<u>05/02/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	No
The Medicines Company (MDCO) / Cleviprex (Clevidipine)						
	Short-Term Hypertension Associated With Cardiac Surgery	Calcium Channel Blocking Agents	05/02/2008	Yes	Yes Only Candidate with This PMOA for This Indication	Yes
Salix Pharmaceuticals, Ltd. (SLXP) / Colazal Tablet (Balsalazide Disodium)						
	Mild To Moderate Ulcerative Colitis	Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors	<u>05/16/2008</u>	Yes	No Multiple Drugs	No
Abbott Laboratories (ABT) / Kaletra (Lopinavir/Ritonavir)						
	Tablet Formulation For Treatment Of Pediatric HIV/AIDS	Protease Inhibitors	05/19/2008	Yes	Yes Only Candidate with This PMOA for This Indication	No

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? **1st/2nd Drug** -- 1st or 2nd FDA Approved Drug of the Company?

Price and Financial Info

February 2008

Data as of 02/01/2008

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Bristol Myers Squibb Co.	BMY	23.80	47,088.562	22,106,306	10.04	54.94	3,582.0	-17.36%	-4.23%
Cephalon, Inc.	CEPH	65.44	4,387.850	1,584,756	n/a	101.29	731.1	-10.54%	2.59%
CV Therapeutics, Inc.	CVTX	8.34	497.615	852,540	n/a	0	194.8	-36.82%	-23.68%
Eisai Co., Ltd (ADR)	ESALY	40.70	11,565.417	7,692	2.84	0	1,393.8	-21.96%	-8.82%
Eli Lilly & Co.	LLY	51.46	58,371.748	8,141,308	n/a	n/a	n/a	-6.04%	7.09%
Genta Incorporated	GNTA	0.50	15.310	134,146	3.49	3.17	15.5	-82.64%	-69.50%
Johnson & Johnson	JNJ	63.42	181,499.347	15,854,200	n/a	n/a	n/a	-5.35%	7.78%
QLT Inc. (USA)	QLTI	3.79	282.811	524,488	1.65	65	172.2	-59.59%	-46.46%
Regeneron Pharmaceuticals, Inc.	REGN	21.32	1,410.313	633,784	9.32	132.1	397.0	5.18%	18.31%
Spectrum Pharmaceuticals, Inc.	SPPI	2.53	78.989	119,756	1.33	0	65.8	-61.14%	-48.00%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,

March 2008

Data as of 02/01/2008

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Alcon, Inc.	ACL	140.86	41,964.040	399,938	17.22	27.92	1,625.8	19.16%	32.30%
AVANT Immunotherapeutics, Inc.	AVAN	0.69	51.182	232,299	n/a	0	20.3	-48.51%	-35.38%
Biovail Corporation (USA)	BVF	13.25	2,133.564	803,412	3.42	0	416.5	-36.93%	-23.80%
Bristol Myers Squibb Co.	BMY	23.80	47,088.562	22,106,306	10.04	54.94	3,582.0	-17.36%	-4.23%
GlaxoSmithKline plc (ADR)	GSK	47.06	129,602.044	2,306,021	12.63	69.63	6,215.2	-13.98%	-0.85%
Johnson & Johnson	JNJ	63.42	181,499.347	15,854,200	n/a	n/a	n/a	-5.35%	7.78%
Merck & Co., Inc.	MRK	45.87	99,839.132	21,675,328	n/a	n/a	n/a	1.64%	14.77%
Neurochem Inc. (USA)	NRMX	1.73	84.505	207,776	6.74	185.54	70.0	-89.78%	-76.65%
POZEN Inc.	POZN	12.40	368.339	352,772	9.67	0	78.8	-26.71%	-13.58%
Schering-Plough Corporation	SGP	20.45	33,131.414	30,067,480	2.53	34.43	12,561.0	-18.05%	-4.91%
Sciele Pharma Inc.	SCRX	24.00	855.565	1,191,642	684.45	76.59	204.2	-1.36%	11.78%
Shire plc (ADR)	SHPGY	55.73	10,332.275	1,408,049	n/a	111.88	562.9	-13.54%	-0.41%
Solvay S.A. (ADR)	SVYSY	125.75	10,651.167	1,193	2.91	43.96	630.3	-16.17%	-3.03%
Sucampo Pharmaceuticals, Inc.	SCMP	12.94	539.981	19,432	6.20	0	89.7	n/a	
Warner Chilcott Ltd.	WCRX	16.99	4,257.346	704,819	n/a	96.59	26.8	13.95%	27.09%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,

April 2008

Data as of 02/01/2008

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Abbott Laboratories	ABT	57.28	88,513.184	8,627,916	n/a	n/a	n/a	8.34%	21.48%
Akorn, Inc.	AKRX	7.36	645.786	525,291	12.00	0.5	10.3	20.85%	33.99%
Discovery Laboratories, Inc.	DSCO	1.88	162.790	1,014,306	8.03	70.88	32.4	-24.80%	-11.67%
Ligand Pharmaceuticals Inc.	LGND	4.21	401.775	509,467	10.40	6.99	98.4	-66.80%	-53.66%

Progenics Pharmaceuticals, Inc.	PGNX	17.01	505.349	923,005	3.21	0	145.7	-43.77%	-30.63%
Salix Pharmaceuticals, Ltd.	SLXP	6.74	320.754	2,378,013	2.93	5.22	70.2	-52.97%	-39.83%
The Medicines Company	MDCO	18.61	964.787	500,386	3.77	0	210.2	-39.70%	-26.56%
Wyeth	WYE	40.35	54,034.301	10,568,056	4.32	69.12	12,919.1	-20.29%	-7.15%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,